Skip to main content

Table 1 Characteristics of treatment groups

From: Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review

Drugs

AL and DP

AL and ACD

AL and ASAQ

AL and AM

AL and AAZ

Age range(months)

6-168

6-180

1.5-120

6-216

6-59

Median (IQR) duration of follow-up (days)

35(22.8-51.8)

35(12.3-42)

28(21-42)

28

42

Number of studies

11

3

13

2

1

Number of patients in AL arm

3343

1861

3054

239

132

Number in comparator arm

4284

1505

2964

237

129